Made Easy: L-Mesitran

Share this article

Made Easy: L-Mesitran

Supported by H&R Healthcare Ltd
Sharon Gardner
31 May 2021

There is growing concern regarding antibiotic resistance, and it is estimated that if no action is taken, antimicrobial drug-resistant diseases could cause 10 million deaths each year by 2050, costing £66 trillion (Interagency Coordinating Group on Antimicrobial Resistance, 2019). As such, clinical studies focused on honey as an antimicrobial are emerging. Honey is a natural and effective therapy with broad-spectrum antimicrobial activity and no risk of resistance, which may potentially reduce use of antibiotics (Yaghoobi et al, 2013). This Made Easy explores the role of natural wound healing remedies, the impact of Medical Grade Honey (MGH) and the range of L-Mesitran® (H&R Healthcare) products.

Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.